Figure 7
Sp1 induces CYP17A1 overexpression by inhibiting DNMT3a-mediated DNA methylation, thus resulting in an increase in DHEA biosynthesis and glioma resistance to TMZ.
Figure 7 | Oncogenesis
Sp1 induces CYP17A1 overexpression by inhibiting DNMT3a-mediated DNA methylation, thus resulting in an increase in DHEA biosynthesis and glioma resistance to TMZ.
